PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase. Issue 1 (18th October 2014)

• Record Type: Journal Article
• Authors: Alonso‐Dominguez, Juan M.; Grinfeld, Jacob; Alikian, Mary; Marin, David; Reid, Alistair; Daghistani, Mustafa; Hedgley, Corinne; O'Brien, Stephen; Clark, Richard E.; Apperley, Jane; Foroni, Letizia; Gerrard, Gareth
• Is Part Of: American journal of hematology. Volume 90:Issue 1(2015:Jan.)
• Page Start: 20
• Page End: 26
• Publication Date: 2014-10-18
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.23857
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The tyrosine kinase inhibitor (TKI) imatinib has revolutionized the management of chronic myeloid leukaemia (CML). However, around 25% of patients fail to sustain an adequate response. We sought to identify gene‐expression biomarkers that could be used to predict imatinib response. The expression of 29 genes, previously implicated in CML pathogenesis, were measured by TaqMan Low Density Array in 73 CML patient samples. Patients were divided into low and high expression for each gene and imatinib failure (IF), probability of achieving CCyR, progression free survival and CML related OS were compared by Kaplan–Meier and log‐rank. Results were validated in a second cohort of 56 patients, with a further technical validation using custom gene‐expression assays in a conventional RT‐qPCR in a sub‐cohort of 37 patients. Patients with low <italic>PTCH1</italic> expression showed a worse clinical response for all variables in all cohorts. <italic>PTCH1</italic> was the most significant predictor in the multivariate analysis compared with Sokal, age and EUTOS. <italic>PTCH1</italic> expression assay showed the adequate sensitivity, specificity and predictive values to predict for IF. Given the different treatments available for CML, measuring <italic>PTCH1</italic> expression at diagnosis may help establish who will benefit best from imatinib and who is better selected for second generation TKI. Am. J. Hematol. 90:20–26, 2015. © 2014 Wiley Periodicals, Inc.</p> </abstract>